Peritoneal Tuberculosis during Infliximab Treatment in a Patient with Ulcerative Colitis Despite a Negative Quantiferon Test

Infliximab is an IgG1 antitumor necrosis factor monoclonal antibody that is commonly used to treat inflammatory bowel disease (IBD) and other autoimmune disorders. However, it is known to increase the risk of reactivation of latent tuberculosis (LTBI) due to its capability to disrupt TB granulomas....

Descripción completa

Detalles Bibliográficos
Autores principales: Colombo, Anna, Giuffrè, Mauro, Crocè, Lory Saveria, Venturini, Sergio, Sablich, Renato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145928/
https://www.ncbi.nlm.nih.gov/pubmed/33946817
http://dx.doi.org/10.3390/pathogens10050535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145928/
https://www.ncbi.nlm.nih.gov/pubmed/33946817
http://dx.doi.org/10.3390/pathogens10050535

Ejemplares similares